Harness attend Target ALS Annual Meeting

We are very excited to be attending the 2024 Target ALS annual meeting in Boston this week (7–9 May)!

Madeleine Wakeling, our SVP Programme Management & Operations will be representing Harness so if you're attending the conference, please reach out and say hello!

Our vision

Building the leading platform for physiological upregulation of neurodegenerative disease targets to enable truly disease-modifying therapies.

Our approach

Deep expertise & unique capabilities in RNA biology & neurodegeneration

High value targets

Ready to scale

Learn more

Our programmes

Preventing the progression of Huntington’s Disease

Discover more

Our news

View all